



These additions apply to Exchange formularies and are effective 2/16/24.

Additions

- **Meibo (perfluorohexyloctane ophthalmic solution)** – Pharmacy benefit, Non-Preferred brand, PA
- **Ngenla (somatrogon-ghla)** – Pharmacy benefit, Non-Preferred brand, PA
- **Pradaxa (dabigatran etexilate) oral packet** – Pharmacy benefit, Non-Preferred brand, PA
- **Liqrev (sildenafil citrate oral suspension)** – Pharmacy benefit, Non-Preferred brand, PA
- **Litfulo (ritlecitinib)** – Pharmacy benefit, Non-Preferred brand, PA and QL of 1 per day
- **Xdemvy (lotilaner ophthalmic solution)** – Pharmacy benefit, Non-Preferred brand, PA and QL of 1 treatment per 365 days
- **Xciati (clindamycin 2% vaginal gel)** – Pharmacy benefit, Non-Preferred brand
- **Cuvrior (trientine)** – Pharmacy benefit, Non-Preferred brand, PA
- **Altuviiiio (antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl)** – Medical benefit, no PA
- **Olpruva (sodium phenylbutyrate)** – Pharmacy benefit, Non-Preferred brand, PA
- **Uzedy (risperidone extended-release)** – Medical benefit, no PA
- **Beyfortus (nirsevimab-alip)** – Pharmacy benefit, no PA, no copay
- **Sogroya (somapacitan-beco)** – Pharmacy benefit, Non-Preferred brand, PA
- **Lumryz (sodium oxybate)** – Pharmacy benefit, Non-Preferred brand, PA
- **Akeega (niraparib and abiraterone)** – Pharmacy benefit, Non-Preferred brand, PA
- **Aphexda (motixafortide)** – Medical benefit
- **Suflave (PEG 3350-KCl-NaCl-NaSulf-MgSul oral solution)** – Pharmacy benefit, Generic, Preventative \$0

Changes

- **Ingrezza (valbenazine)** – Pharmacy benefit, update to PA criteria, add Chorea associated with Huntington's disease (HD) indication
- **Bylvay (odevixibat)** – Pharmacy benefit, update to PA criteria, add cholestatic pruritis indication
- **Ilaris (canakinumab)** – Pharmacy benefit, update to PA criteria, add Gout Flares indication
- **Myfembree (relugolix-estradiol-norethindrone acetate)** – Pharmacy benefit, update to PA criteria, add Pain Associated With Endometriosis indication
- **Reblozyl (luspatercept-aamt)** – Medical benefit, new indication
- **Rinvoq (upadacitinib)** – Pharmacy benefit, update to PA criteria, add Crohn's disease indication